Product Description
Studies in type 2 diabetic animal models have demonstrated that Atrogi’s lead drug candidate ATR-258 lowers blood glucose to healthy levels independent of insulin. In addition, the drug candidate enhances insulin sensitivity and lowers insulin production. The treatment can potentially function as a stand-alone or a combination therapy. (Sourced from: https://atrogi.com/our-solution/)
Mechanisms of Action: ADRB2 Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Atrogi AB
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
![Map of Global Clinical Trials for ATR-258](https://pryzm-maps.s3.us-west-2.amazonaws.com/9149current_maps.png)
Countries in Clinic: Germany, Sweden
Active Clinical Trial Count: 2
Highest Development Phases
Phase 1: General Diabetes|Healthy Volunteers|Type 2 Diabetes
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
Attractive 2 | P1 |
Completed |
Healthy Volunteers|General Diabetes |
2024-05-27 |
|
ATR-258-study-1 | P1 |
Completed |
Type 2 Diabetes |
2023-10-04 |